Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 4/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102574 | 0.83 | POLA1 (0.35) | — | |
| SCHEMBL2461933 | 0.79 | POLA1 (0.34) | — | |
| SCHEMBL31070849 | 0.79 | POLA1 (0.30) | — | |
| SCHEMBL28737678 | 0.76 | NPC1 (0.38) | KCNH2CES2CES1LMNAKDM4E | |
| SCHEMBL7851780 | 0.76 | L3MBTL1 (0.41) | CES2CES1HTTNPC1L3MBTL1 | |
| SCHEMBL1726141 | 0.74 | KDM1A (0.39) | MMP2MMP3MMP9 | |
| SCHEMBL6938598 | 0.73 | L3MBTL1 (0.39) | CES2CES1HTTNPC1L3MBTL1 | |
| SCHEMBL11528752 | 0.73 | — | — | |
| SCHEMBL28841075 | 0.72 | KCNH2 (0.43) | KCNH2CES2CES1NAAALMNA | |
| SCHEMBL29091452 | 0.72 | NPC1 (0.40) | KCNH2CES2CES1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820061-B2 | Titanium oxide and alumina alkali metal compositions | SIGNA CHEMISTRY, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090266771-A1 | TITANIUM OXIDE AND ALUMINA ALKALI METAL COMPOSITIONS | SIGNA CHEMISTRY, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7560606-B2 | Titanium oxide and alumina alkali metal compositions | SIGNA CHEMISTRY, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080063596-A1 | TITANIUM OXIDE AND ALUMINA ALKALI METAL COMPOSITIONS | SIGNA CHEMISTRY LLC (US) | 2008-03-13 | — | — | US | disclosed |
| CN-101060928-A | Titanium oxide and aluminum oxide alkali metal compositions | SIGNA CHEMISTRY LLC (US) | 2007-10-24 | — | — | CN | disclosed |
| US-7259128-B2 | Titanium oxide and alumina alkali metal compositions | SIGNA CHEMISTRY, LLC (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1807199-A2 | TITANIUM OXIDE AND ALUMINA ALKALI METAL COMPOSITIONS | SIGNA CHEMISTRY LLC (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006036697-A2 | TITANIUM OXIDE AND ALUMINA ALKALI METAL COMPOSTIONS | SIGNA CHEMISTRY LLC (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060073968-A1 | Titanium oxide and alumina alkali metal compositions | SIGNA CHEMISTRY LLC (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063596-A1 | TITANIUM OXIDE AND ALUMINA ALKALI METAL COMPOSITIONS | KCNN1, ATP1A1, KCNJ11 | KCNH2 20/4885CES2 4877/4885CES1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.